| Today’s Big NewsJan 26, 2024 |
|
This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way, providing a robust and adaptable manufacturing platform for gene therapy breakthroughs.
|
|
| By Max Bayer,Gabrielle Masson Coming off one of the worst years for IPOs in recent history, two new upsized IPOs have offered a stretching ray of hope that 2024 may not be so bad after all. |
|
|
|
By James Waldron Consider that IPO window well and truly opened. The day after CG Oncology became the first biotech to join the Nasdaq in 2024, ArriVent BioPharma has now followed suit with its own upsized offering. |
By Angus Liu The combination of Merck's Keytruda and Pfizer and Astellas' Padcev recently made waves in bladder cancer—and the broader oncology world—by delivering a massive life-extension benefit. Now, Merck can claim another positive readout for Keytruda in bladder cancer, although this one is short of a home run. |
By Andrea Park The violations were outlined in U.S. Department of Transportation documents obtained in a records request by the Physicians Committee of Responsible Medicine—an animal research advocacy group that has previously claimed that Neuralink mistreats its animal subjects, in accusations that Neuralink has denied. |
By Gabrielle Masson Bristol Myers Squibb is proving its worth as an M&A competitor, coming out on top not once but twice in terms of fresh acquisitions. Most recently, the pharma’s $4.1 billion bid for radiopharmaceuticals biotech RayzeBio was enough to beat out two other companies that also put down offers. |
By Kevin Dunleavy Shortly after Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended refusal of marketing authorization for Apellis’ geographic atrophy (GA) drug Syfovre (pegcetacoplan injection), the company said it will appeal the guidance. |
By Conor Hale When the Pixel 8 Pro was first announced last October, Google said its sensor was well-suited to gauging the warmth of household objects, but that it shouldn’t be used to check someone out for a fever. That’s changed with the agency’s green light. |
By Conor Hale The low-profile Jewel patch aims to overcome the problems seen with traditional wearable cardioverter defibrillators, with their bulky hardware, straps and separate battery pack. |
By Fraiser Kansteiner In late 2022, GSK, Sanofi and Takeda signed on with a partnership of local agencies to advance biologic manufacturing in Singapore. Now, a little more than a year later, AbbVie is getting in on the action by starting a major production expansion in the Garden City. |
Fierce podcastsDon’t miss an episode |
| | While it’s a known fact that women, on average, live longer than men, a recent report unveils a nuanced reality—women also spend more of their lives grappling with poor health. This week on “The Top Line,” Ayla Ellison, editor-in-chief of Fierce Healthcare and Life Sciences, explores the root causes behind this disparity and the multifacted nature of the women’s health gap. |
|
|---|
|
|
|
This white paper explains how Resilience utilizes a Stage-Gate approach to technology transfer and biomanufacturing. Built on proven methods used across industries, the Stage-Gate approach mitigates risk while shortening cycle times throughout the project lifecycle. Download now.
|
|
| WhitepaperThe road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
